Acta Haematologica · 2005 · 42 citations · 19 references
MedicinePharmacologyPharmacotherapyBiopharmaceuticsClinical PharmacologyIron Metabolism DisordersAnemiaChelation TherapyDeferoxamine TherapyIron Chelation TherapyIron DeficiencyIron Deficiency DisordersAdverse Effects Of DeferoxamineAspartate Aminotransferase ElevationBody Iron StoresDeferoxamine Clinical EfficacySerum Aspartate AminotransferaseSerum Ferritin AssessmentThalassemia Iron Overload ManagementThalassemia Major
Deferiprone at a dose of 75 mg/kg/day is not sufficiently effective to maintain iron stores at a level which has been considered safe in all patients with iron overload. Our main aim was to determine the safety of long-term therapy with high-dose (100 mg/kg/day) deferiprone. A secondary aim was to determine the efficacy of this high dose. Twelve thalassemia major patients received deferiprone at a dose of 100 mg/kg/day over 2 years. Transient aspartate aminotransferase increase (8 patients), gastrointestinal discomfort (3 patients) and arthralgia (2 patients) were the most commonly reported side effects. None of the patients discontinued therapy. The mean serum ferritin level fell from 3,901 +/- 3,618 to 1,790 +/- 2,205 microg/l after 2 years (p < 0.05). Five of the 12 patients continued to receive deferiprone for an additional 3 years. No new side effects were encountered. The mean serum ferritin level in this subgroup was initially 2,510 +/- 332 microg/l and dropped to 1,511 +/- 664 microg/l after 5 years (p < 0.05). Liver iron levels at the end of the 2-year study ranged from 1.0 to 30.9 mg/g dry weight, 3 of the patients having levels above 15 mg/g.
19
SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR
MariaGrazia Zurlo, Piero De Stefano, Caterina Borgna‐Pignatti et al. · The Lancet · 1989 · 616 citations
Medicine, Biology, Hematology +5